# Bispecific Antibody Development Programs Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/bispecific-antibody-development-programs-guidance-for-industry/16d40dbb-63de-4441-b656-7949b4a1018d

> FDA guidance document: Bispecific Antibody Development Programs Guidance for Industry. Issue date: May 24, 2021. Get complete insights and analysis.

---

## Details

- Title: Bispecific Antibody Development Programs Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2021-05-24
- Last Changed: 2021-05-24
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2019-D-0621">FDA-2019-D-0621</a>

## Related Documents

- [M9 Biopharmaceutics Classification System-Based Biowaivers](https://www.globalkeysolutions.net/guidances/guidance-document/m9-biopharmaceutics-classification-system-based-biowaivers/bf9d33a6-a7bf-4b4e-bf7a-2a88d1e6d1cf)
- [Field Alert Report Submission: Questions and Answers Guidance for Industry:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/field-alert-report-submission-questions-and-answers-guidance-for-industry-guidance-for-industry/b554a2c6-8278-4f9a-a91c-72bcdd411715)
- [Elemental Impurities in Drug Products Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/elemental-impurities-in-drug-products-guidance-for-industry/5931c496-e20b-426d-915b-0856db49e99e)